Dr Olivia Burn received her PhD from the University of Otago under the supervision of Dr Robert Weinkove within the Cancer Immunotherapy programme at the Malaghan Institute. Her thesis was centred around the innate-like T-cell populations natural killer T (NKT) cells and Vγ9Vδ2 T-cells and how these can be harnessed to enhance cancer vaccine effectiveness, with a particular focus on breast cancer.
Dr Burn is currently working as a postdoctoral research fellow in the Hermans Laboratory.
Read more about her research here.
Related news
TVNZ Breakfast interview with Dr Olivia Burn: Breast cancer research
8 July 2022
Breast cancer research shows promise for future vaccine development
5 July 2022
Dr Olivia Burn: Uncovering the clues to arrest cancer cells
21 July 2021
Research for Life latest funding in support of Malaghan researchers
29 October 2018
Publications
2022
Farrand K, Holz LE, Ferrer-Font L, Wilson MD, Ganley M, Minnell JJ, Tang CW, Painter GF, Heath WR, Hermans IF, Burn OK (2022). Using Full-Spectrum Flow Cytometry to Phenotype Memory T and NKT Cell Subsets with Optimized Tissue-Specific Preparation Protocols. Curr Protoc. 2(7):e482.
Burn OK, Farrand K, Pritchard T, Draper S, Tang CW, Mooney AH, Schmidt AJ, Yang SH, Williams GM, Brimble MA, Kandasamy M, Marshall AJ, Clarke K, Painter GF, Hermans IF, Weinkove R (2022). Glycolipid-peptide conjugate vaccines elicit CD8+ T-cell responses and prevent breast cancer metastasis. Clin Transl Immunology. 11(7):e1401
Prasit KK, Ferrer-Font L, Burn OK, Anderson RJ, Compton BJ, Schmidt AJ, Mayer JU, Chen CJ, Dasyam N, Ritchie DS, Godfrey DI, Mattarollo SR, Dundar PR, Painter GF, Hermans IF (2022). Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. Oncoimmunology. 11(1):2081009
2021
O K Burn, T E Pankhurst, G F Painter, L M Connor, I F Hermans (2021). Harnessing NKT cells for vaccination. Oxford Open Immunology. 2(1):iqab013